Lates News

Each AI flash news, Open Source Securities issued a research report on August 21, giving Buy rating to Baoli Tianheng (688506.SH). The rating reasons mainly include: 1) Iza-bren (BL-B01D1) has been granted BTD by the FDA for EGFR-mutated NSCLC; 2) The domestic NDA for BL-B01D1 is imminent, with three global registration clinical trials already underway in 2025; 3) Differentiated ADC platform + global leading multi-antibody platform FIC and BIC pipeline. (Daily Economic News)